Bionomics’ (BNOX) Buy Rating Reaffirmed at HC Wainwright

Bionomics (NASDAQ:BNOX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They presently have a $8.00 price objective on the stock.

Bionomics Stock Down 7.3 %

Bionomics stock traded down $0.06 during mid-day trading on Thursday, reaching $0.78. 19,643,334 shares of the company traded hands, compared to its average volume of 335,962. The firm’s 50 day moving average price is $0.82 and its 200 day moving average price is $0.98. Bionomics has a 52-week low of $0.65 and a 52-week high of $6.41.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.